Kornimate/medical-research-clean huggingface dataset:
early active rehabilitation after arthroscopic rotator cuff repair

Conditions: Full Thickness Rotator Cuff Tear

Summary: the purpose of the study is to compare two different rehabilitation protocols after arthroscopic rotator cuff surgery.


Eligibility criteria:
inclusion criteria: * surgery of the rotator cuff after full thickness tear * informed consent * understanding german language exclusion criteria: * previous surgery of the shoulder * neurological or systemic diseases with impairment of shoulder function
neck kinesiotherapy and massage in tinnitus treatment

Conditions: Subjective Tinnitus

Summary: the primary aim of this study is to investigate the effectiveness of cervical spine kinesiotherapy and massage in tinnitus treatment. furthermore, we investigate if there is a link between cervical spine range of motion and cervical muscles tension and tinnitus.

the study is planned with power of 80%. a total of 118 adult patients with subjective tinnitus are divided into two groups: kinesiotherapy group (n=59) and waiting list group (n=59).kinesiotherapy group receives a complex set of cervical spine exercises and neck massage for consecutive 10 working days (entire treatment takes two weeks). each visit lasts around 30 minutes. patients from kinesiotherapy group will fill the outcome measures on the following time points: (a) time point 0 - baseline (b) time point 1- two weeks after the baseline (c) time point 2- four weeks after the baseline. individuals from waiting list group are enrolled on a waiting list and do not receive any treatment. they undergo assessment at three time points corresponding to kinesiotherapy group i.e time point 0, time point 1 and time point 2. .

Eligibility criteria:
inclusion criteria: -adult patients with subjective tinnitus experienced in the ears or in the head (temporary and constant tinnitus) with and without sensorineural hearing loss. exclusion criteria: * other tinnitus treatment in last 6 months, * objective tinnitus, * external and middle ear pathology, * acute infections, conditions with fever * bleedings or risk of bleeding * severe respiratory and circulatory insufficiency * vasculitis, thrombophlebitis, * pregnancy * acute arthritis and periarticular soft tissues inflammation in the cervical region, * severe pains in different locations, * advanced osteoporosis * uniformed services. * cervical spine instability, cervical disc herniation, cervical radiculopathy. * status post cervical spine surgery. * status post lumbar puncture, status post computed tomography with contrast. * lack of cooperation between the patient and the therapist, cognitive impairment. * atherosclerosis, vertebrobasilar insufficiency.

Keywords: subjective tinnitus, massage post isometric relaxation exercises kinesiotherapy
a trial investigating the pharmacodynamic properties of nn1218 in subjects with type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial is conducted in europe. the aim of this trial is to investigate the pharmacodynamic properties (the effect of the investigated drug on the body) of nn1218 in subjects with type 1 diabetes.


Eligibility criteria:
inclusion criteria: * type 1 diabetes mellitus for more than 12 months * treated with multiple daily insulin injections or continuous subcutaneous insulin infusion for more than 12 months * body mass index (bmi) between 18.0-28.0 kg/m\^2 (both inclusive) exclusion criteria: * subject who has donated any blood or plasma in the past month or more than 500 ml within 3 months prior to trial start * smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day) * not able or willing to refrain from smoking and use of nicotine substitute products during the inpatient period
theta-burst rtms in schizophrenia to ameliorate negative and cognitive symptoms

Conditions: Transcranial Magnetic Stimulation Repetitive; Schizophrenia

Summary: the major target of the study is to confirm the safety and efficacy of our augmented protocol of theta-burst tms in schizophrenia. our aim is to confirm the beneficial effects of rtms treatment on multiple aspects of the disorder such as (1) clinical aspect in terms of panss, (2) cognitive aspect such as emotion recognition (er) and working memory (wm) / distractor filtering (df) performance, and (3) neurobiology in terms of electrophysiology correlates of er, wm and df such as event related theta synchronization, resting state theta power, and network connectivity. response prediction to (theta-burst) tb-rtms will be the exploratory part of the study.


Eligibility criteria:
inclusion criteria: 1. diagnosis of schizophrenia or schizoaffective disorder; 2. clinically stabilized on antipsychotic: a stable dose of antipsychotic medication for \>4 weeks; 3. age 18-55 years, and 4. presence of negative symptoms (based on panss): a negative subscore ≥16 points and \[one of items n1-n7 scoring ≥4 or two items n1-n7 scoring ≥3\] exclusion criteria: 1. any significant neurological illness; 2. mental retardation 3. history of head injury with loss of consciousness for more than 1 hour 4. history of epileptic seizures or epileptic activity on the baseline eeg (evaluated by an expert in clinical eeg and epilepsy), 5. alcohol or drug abuse within the past 3 months, and 6. depressive episode or antidepressant treatment in the past 4 weeks. 7. severe positive symptoms inferfere with cognitive tests 8. ect in the medical history 9. implanted pacemaker, implanted drug pump, cochlear implant, implanted defibrillator, implanted neurostimulator or any other tms incompatible implanted metal device 10. skin surface is severly injured in the stimulated region of the skull 11. sclerosis multiplex 12. pregnancy 13. severe sleep deprivation 14. severe heart failure 15. increased intracranial pressure 16. untreated migrain
a phase 3 efficacy study of dimebon in patients with moderate to severe alzheimer's disease

Conditions: Alzheimer Disease

Summary: no dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. therefore, this study evaluates the safety and efficacy of dimebon in patients with moderate-to-severe ad who are receiving existing background therapy with memantine.

this study was terminated on may 7, 2010 due to modification of the dimebon development plan following the lack of demonstration of efficacy in the completed dim14 (connection) study. the study was not terminated due to any safety findings. dimebon has been well-tolerated in clinical trials. demonstration of efficacy for dimebon in alzheimer's disease is pending completion of the ongoing dim18 (concert) study.

Eligibility criteria:
inclusion criteria: * are men and women ≥ 50 years of age with a diagnosis of alzheimers disease. * have a mini-mental state exam between 5 and 14 inclusive. * have been taking the medication memantine (ie., namenda) for at least six months prior to this study. * must have a caregiver who assists the patient at least five days per week for at least three hours per day, who can accompany patient to study visits, and who has an intimate knowledge of the patient's health states and personal care. exclusion criteria: * have taken medicines for alzheimers disease other than memantine (e.g., donepezil, rivastigmine, galantamine, tacrine) within 2 months prior to this study. * dementia other than alzheimers disease. * any medical condition or reason that interferes with the ability of the patient to participate in or complete the trial or places the patient at undue risk, as judged by the study doctor.

Keywords: alzheimer disease moderate-to-severe memantine safety and efficacy
apneic oxygenation by transnasal humidified rapid insufflation ventilator exchange obstructive sleep apnea patients

Conditions: Obstructive Sleep Apnea Syndrome

Summary: the purpose of the study is to compare effectiveness of different methods of achieving oxygenation in obstructive sleep apnea patients. the investigators intend to compare transnasal humidified rapid-insufflation ventilator exchange (thrive) combined with nasopharyngeal airway with thrive alone.

with the increasing prevalence of obesity, the prevalence of osa is also rising, ranging from 9% to 25% in the general adult population. patients with osa have features of an anatomically tricky airway due to a crowded collapsible pharyngeal space, compounded by physiological problems related to lower functional residual capacity and increased oxygen consumption, leading to faster oxygen desaturation. meanwhile, patients with osa, compared to patients without osa, have a 3-4 times higher risk of difficult intubation, difficult mask ventilation, or both. apnoea time is a potentially hazardous period during induction of anesthesia and it is particularly so in patients with osa. osa patients undergoing general anesthesia gave rise to many concerns and challenges, and strategies to extend the apneic time were required. identifying the most effective method of oxygenating osa patients can therefore significantly improve the safety of delivering general anaesthesia to these patients.

Eligibility criteria:
inclusion criteria: * patients aged between 18 and 75 years requiring general anesthesia * american society of anesthesiologists (asa) physical status classification system: i - iii * diagnosed as osa. exclusion criteria: * patients with chronic respiratory disease, uncontrolled hypertension, ischemic heart disease, congestive heart failure, increased intracranial pressure, gastroesophageal reflux disease, * patients' arterial hemoglobin saturation \< 98% after preoxygenation, * patients were nasal obstruction * patients with previous or anticipated difficult facemask ventilation or intubation, * patients with known allergy or contraindication to propofol, remifentanil, rocuronium, or midazolam. * patients who were unable to give informed consent

Keywords: obstructive sleep apnea thrive apnea time nasopharyngeal nasopharyngeal airway
determination of the effects of noise level in the operating room

Conditions: Noise; Adverse Effect; Noise Induced Hearing Loss

Summary: the goal of this observational study is to learn about effects of noise in healthy patients undergoing elective surgery.

there are many factors that can negatively affect surgical performance in operating rooms. noise is the most striking of these factors. excessive noise can cause hearing loss, cognitive dysfunction, anxiety, stress-induced increases in cortisol levels, and an increased risk of cardiovascular disease. noise can have negative effects on concentration and performance. at the same time, workplace noise is one of the most important causes of fatigue. one of the anesthesia phases where the sound level reaches the highest levels is the induction phase. with this study, the investigators want to examine the effects on the anesthesia team, the patient and the environment by measuring the noise levels during the induction period, and then train the operating room personnel to examine the effects on this issue. the investigators aim to raise awareness about the development of procedures and training programs for operating room personnel.

Eligibility criteria:
inclusion criteria: * patients over the age of 18, * elective cases to be taken under general anesthesia, * those who do not have a psychiatric disease, * patients without hearing loss exclusion criteria: * patients under the age of 18 * patients who have psychiatric disease * patients who has hearing loss

Keywords: noise induced hearing loss operatin room's noise
exchange transfusion versus plasma from convalescent patients with methylene blue in patients with covid-19

Conditions: COVID-19

Summary: the aim of this project is to introduce way for treatment of patients with severe covid-19 disease with respiratory complications.

study tools and/ or procedure the patients were subjected to the following: clinical parameters: complete history taking and thorough clinical examination 1. laboratory parameters: 2. cbc with differential counts. 3. reticulocytic count. 4. blood film for shistocytes. 5. serum ferritin and transferrin saturation. 6. d dimer. 7. liver function tests, kidney function tests, electrolytes. 8. esr. 9. crp. 10. ldh. 11. viral markers (hcv ab, hbsv ag, hiv ab). 12. adam's 13 assays. 13. serum soluble cd 25. other investigations: 1. chest x ray. 2. pelviabdominal us. 3. ct chest. 4. ecg. 5. echocardiography the patients will be divided into three groups, each group formed of 5 patients with severe covid-19 or on mechanical ventilator receiving standard of care all the groups matched regarding age, sex and the severity of the disease. group i: will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed rbcs daily for 3 days according to daily clinical and investigational follow up group ii will receive iv methylene blue 1 mg/kg iv over 30 minutes with 200 cc plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up. group iii will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed rbcs and iv methylene blue 1 mg/kg iv over 30 minutes with 200 cc plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up. n.b.: convalescent plasma and regular blood will be taken from ministry of health after administrative approval all groups will receive 1. low dose anticoagulant (lmwh 1 mg/kg/day). 2. steroid (methyl prednisone 1 mg/ kg iv daily and according to patients' condition and presence of complications like hemophagocytosis). 3. all allergic precautions if needed like antihistaminics , epinephrine and steroid. close monitoring for: 1. allergic reactions. 2. ecg changes daily. 3. volume overload. 4. complications of other comorbidities like dm or htn. 5. liver function and kidney function and organ dysfunction daily. terms of discontinuation: deterioration of clinical condition or organ functions.

Eligibility criteria:
inclusion criteria: 1. adult patients are 18 years old or above. 2. inpatients diagnosed as severe covid - 19 disease according to who criteria. 3. ct chest with extensive lung disease (ground-glass and consolidative pulmonary opacities). 4. o2 saturation less than 93% resting. 5. respiratory rate equal or more than 30 per minute. exclusion criteria: 1. patients with pregnancy and lactation. 2. renal failure and heart failure. 3. contraindication for plasma or blood transfusion.

Keywords: covid-19 exchange transfusion methylene blue
magnetic resonance imaging of cognitive deficits in the brain of individuals with spinal cord injury

Conditions: Spinal Cord Injury

Summary: in the case of spinal cord injury, rehabilitation is particularly focused on motor skills. non-motor impairments such as thinking difficulties did not receive a lot of attention to date. in this research project, the investigators want to find out how thinking difficulties become noticeable in the brain with spinal cord injury. participation procedure: participants who take part will be asked to come to an examination once. the duration of the examination is between 2 and 2.5 hours (including around 55 minutes in the magnetic resonance imaging scanner, including preparation and follow-up).


Eligibility criteria:
inclusion criteria (with and without spinal cord injury): * male or female * age between 18 and 60 * german native speaker * normal or corrected-to-normal visual acuity additional inclusion criteria (spinal cord injury only): * a diagnosis of traumatic spinal cord injury (sci) * time since injury 12 months or longer * american spinal injury association impairment scale (ais) grade a, b, c and d exclusion criteria (with and without spinal cord injury): * contraindication for magnetic resonance imaging examinations (e.g., cardiac pacemaker etc.) * pregnancy * diagnosis of other psychiatric or neurological disorders (including tumor in the central nervous system) * alcohol and/or drug abuse * confirmed diagnosis of traumatic brain injury * insufficient hand function (not able to hold a pen due to the restricted motor abilities)

Keywords: spinal cord injury neuroimaging cognition executive functions
tomographic and histologic assessment on the influence of the use of a collagen membrane to protect the antrostomy after maxillary sinus floor augmentation.

Conditions: Alveolar Bone Loss; Alveolar Bone Resorption

Summary: the aim of the present study was to evaluate the dimensional variation and osseointegration of mini-implants at augmented sinus with the antrostomy left unprotected or protected with a collagen membrane.

the schneiderian mucosa will be elevated and the created space will be filled with a natural bovine bone grafting material (cerabone® 1-2 mm, botiss biomaterials gmbh). in ten patients randomly selected (control sties), a native collagen membrane made of porcine dermis (collprotect®, botiss biomaterials gmbh) will be placed on the antrostomy. in another ten patients of the test group, the antrostomy will be left without the membrane. the flaps will be sutured and anti-inflammatory drugs and antibiotics will be administrated to the patients. the sutures will be removed after 7 days. after 6 months of healing, two mini-implants with different surface will be installed and retrieved after further 3 months for histomorphometric evaluations. cbcts will be taken for all patients before surgery (t0), after 1 week from sinus floor augmentation (t1) and after 9 months of healing (t2) and evaluation of dimensional variations over time of soft and hard tissues will be performed.

Eligibility criteria:
inclusion criteria: * presence of an edentulous atrophic zone in the posterior segment of the maxilla * height of the sinus floor ≤4 mm. * desiring a prosthetic restoration of the zone using a fix prosthesis supported by implants * ≥ 21 years of age * good general health * no contraindication for oral surgical procedures * not being pregnant. exclusion criteria:the patients will be excluded if they present: * a systemic disordered. * had a chemotherapic or radiotherapeutic treatment. * are smokers \>10 cigarettes per day * have an acute or a chronic sinusitis. * had a previous bone augmentation procedures in the zone of interest.

Keywords: antrostomy maxillary sinus augmentation collagen membrane biomaterial
an evaluation of tilmanocept by iv injection using spect/ct vs pet imaging in subjects with liver metastases.

Conditions: Liver Metastases; Colorectal Carcinoma

Summary: estimation of the concordance of tc 99m localization in liver metastases from colorectal carcinoma using spect/ct imaging and abdominal fdg (pet)/ct imaging per subject.

this is a prospective, open-label, single-center, comparator study of iv injected tc 99m tilmanocept in the localization and detection of liver metastases in subjects with confirmed colorectal carcinoma (crc). the study will be divided into two cohorts. if it was determined that additional enrollment would not provide meaningful data, for example no metastatic liver lesions were visualized by tc 99m tilmanocept for any of the subjects in the cohort, enrollment into cohort 2 would begin and 3 subjects would be enrolled followed by a review of the imaging and safety data. this study is designed to evaluate the safety and tolerability of tc 99m tilmanocept administered intravenously. spect/ct imaging of the subject's abdominal cavity will be reviewed to establish concordance with fdg pet imaging.

Eligibility criteria:
inclusion criteria: * the subject has provided written informed consent with health information portability and accountability act (hipaa) authorization before the initiation of any study-related procedures. * subjects must be ≥18 years old; * the subject must have a diagnosis of adenocarcinoma of the colon and/or rectum with fdg pet/ct confirmed metastases to the liver; * the subjects must have an eastern cooperative oncology group (ecog) performance status of 0-3; * the subject must be at least 4 weeks past any major intraabdominal surgery, including surgery to the liver; * subjects with prior malignancies other than colon and/or rectum cancer are allowed, provided they have been treated with curative intent, and have no evidence of recurrence of that malignancy; * each subject must have no more than 10 qualifying liver lesions that have been clinically confirmed metastatic adenocarcinoma of the colon by fdg pet/ct imaging. * if of childbearing potential, the subject has a negative urine pregnancy test within 48 hours before administration of tc 99m tilmanocept, has been surgically sterilized, or has been postmenopausal for at least 1 year exclusion criteria: * the subject is pregnant or lactating. * the subject has undergone any liver surgery, exclusive of a biopsy. * the subject has known sensitivity to dextran. * the subject has had preoperative chemotherapy, immunotherapy, or radiation therapy within the 10 days prior to tc 99m tilmanocept administration * before the administration of tc 99m tilmanocept, has received any radiopharmaceutical within 7 radioactive half-lives of that radiopharmaceutical * has received an investigational product within the 30 days prior to tc 99m tilmanocept administration

Keywords: adenocarcinoma, colorectal carcinoma, liver metastases
covid-19 sars-cov-2 antibody testing study

Conditions: Healthy

Summary: sats is a single site feasibility study to assess the practical and psychological feasibility of using rapid covid antibody testing of blood obtained from fingertip pin-pricks.

sats is a feasibility study conducted at a single site - king's college london and south london and maudsley staff working at the institute of psychiatry, psychology and neuroscience (ioppn) at denmark hill, london, england. the practical and psychological feasibility of using rapid covid antibody testing of blood obtained from fingertip pin-pricks will be assessed.

Eligibility criteria:
inclusion criteria: * king's college staff member * aged 18 years or over * able to freely give informed consent exclusion criteria: the participant may not enter the study if any of the following apply: * known to have an infectious disease including a current sars-cov-2 infection. * any significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the research study, or may influence the result of the research study, or the participant's ability to participate in the research study. examples of disorders or diseases which would be excluded include: * medically diagnosed bleeding disorder; * medically diagnosed platelet disorder; * anticoagulant medication.